← Back to All US Stocks

Vsee Health, Inc.. (VSEEW) Stock Fundamental Analysis & AI Rating 2026

VSEEW Nasdaq Services-Health Services DE CIK: 0001864531
Recently Updated • Analysis: Apr 18, 2026 • SEC Data: 2025-12-31
STRONG SELL
90% Conf
Pending
Analysis scheduled

📊 VSEEW Key Takeaways

Revenue: $14.6M
Net Margin: -100.6%
Free Cash Flow: $-3.5M
Current Ratio: 0.51x
Debt/Equity: 0.50x
EPS: $-0.73
AI Rating: STRONG SELL with 90% confidence
Vsee Health, Inc.. (VSEEW) receives a STRONG SELL rating with 90% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $14.6M, net profit margin of -100.6%, and return on equity (ROE) of -269.8%, Vsee Health, Inc.. demonstrates mixed fundamentals in the Services sector. Below is our complete VSEEW stock analysis for 2026.

Is Vsee Health, Inc.. (VSEEW) a Good Investment?

Claude

VSee Health is a financially distressed health services company with zero revenue growth, operating losses exceeding revenue (-$9.6M operating loss on $14.6M revenue), and negative free cash flow (-$3.5M). While the 50%+ gross margin indicates core unit economics could work, the company is burning cash rapidly with a critically weak liquidity position (0.51x current ratio) and limited runway without dramatic operational turnaround or capital infusion.

Why Buy Vsee Health, Inc.. Stock? VSEEW Key Strengths

Claude
  • + Solid gross margin of 50.3% suggests core business model viability if scaled efficiently
  • + Maintains $5.3M cash balance providing near-term operational runway
  • + Conservative capital expenditure approach minimizes discretionary cash burn

VSEEW Stock Risks: Vsee Health, Inc.. Investment Risks

Claude
  • ! Zero revenue growth with operating losses of $9.6M exceeding total operating revenue
  • ! Critical liquidity crisis: current ratio of 0.51x indicates insufficient current assets to cover liabilities
  • ! Negative free cash flow of $3.5M annually with monthly burn rate threatening company viability within 12-18 months

Key Metrics to Watch

Claude
  • * Quarterly revenue growth rate and customer retention
  • * Operating cash flow improvement and path to positive cash operations
  • * Monthly cash burn rate and remaining runway before depletion

Vsee Health, Inc.. (VSEEW) Financial Metrics & Key Ratios

Revenue
$14.6M
Net Income
$-14.7M
EPS (Diluted)
$-0.73
Free Cash Flow
$-3.5M
Total Assets
$22.4M
Cash Position
$5.3M

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

VSEEW Profit Margin, ROE & Profitability Analysis

Gross Margin 50.3%
Operating Margin -65.6%
Net Margin -100.6%
ROE -269.8%
ROA -65.6%
FCF Margin -23.8%

VSEEW vs Services Sector: How Vsee Health, Inc.. Compares

How Vsee Health, Inc.. compares to Services sector averages

Net Margin
VSEEW -100.6%
vs
Sector Avg 10.0%
VSEEW Sector
ROE
VSEEW -269.8%
vs
Sector Avg 16.0%
VSEEW Sector
Current Ratio
VSEEW 0.5x
vs
Sector Avg 1.5x
VSEEW Sector
Debt/Equity
VSEEW 0.5x
vs
Sector Avg 0.7x
VSEEW Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Vsee Health, Inc.. Stock Overvalued? VSEEW Valuation Analysis 2026

Based on fundamental analysis, Vsee Health, Inc.. shows some fundamental concerns relative to the Services sector in 2026.

Return on Equity
-269.8%
Sector avg: 16%
Net Profit Margin
-100.6%
Sector avg: 10%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.50x
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Vsee Health, Inc.. Balance Sheet: VSEEW Debt, Cash & Liquidity

Current Ratio
0.51x
Quick Ratio
0.51x
Debt/Equity
0.50x
Debt/Assets
75.7%
Interest Coverage
-20.54x
Long-term Debt
$2.7M

VSEEW Revenue & Earnings Growth: 5-Year Financial Trend

VSEEW 5-year financial data: Year 2024: Revenue $10.4M, Net Income -$530.0K, EPS $-0.05. Year 2025: Revenue $14.6M, Net Income -$57.7M, EPS $-5.65.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Vsee Health, Inc..'s revenue has grown significantly by 40% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.65 indicates the company is currently unprofitable.

VSEEW Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-23.8%
Free cash flow / Revenue

VSEEW Quarterly Earnings & Performance

Quarterly financial performance data for Vsee Health, Inc.. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $3.4M -$289.7K $-0.02
Q2 2025 $1.7M -$571.4K $-0.11
Q1 2025 $1.6M $62.8K $0.01
Q3 2024 $1.5M -$2.8K $-0.01
Q2 2024 $1.3M -$2.8K $-0.06

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Vsee Health, Inc.. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$3.4M
Cash generated from operations
Stock Buybacks
$44
Shares repurchased (TTM)
Capital Expenditures
$29.9K
Investment in assets
Dividends
None
No dividend program

VSEEW SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Vsee Health, Inc.. (CIK: 0001864531)

📋 Recent SEC Filings

Date Form Document Action
Mar 31, 2026 10-K vsee10k123125.htm View →
Mar 24, 2026 4 xslF345X06/ownership.xml View →
Mar 24, 2026 4 xslF345X06/ownership.xml View →
Mar 6, 2026 4 xslF345X05/ownership.xml View →
Mar 6, 2026 4 xslF345X05/ownership.xml View →

Frequently Asked Questions about VSEEW

What is the AI rating for VSEEW?

Vsee Health, Inc.. (VSEEW) has an AI rating of STRONG SELL with 90% confidence, based on fundamental analysis of SEC EDGAR filings.

What are VSEEW's key strengths?

Claude: Solid gross margin of 50.3% suggests core business model viability if scaled efficiently. Maintains $5.3M cash balance providing near-term operational runway.

What are the risks of investing in VSEEW?

Claude: Zero revenue growth with operating losses of $9.6M exceeding total operating revenue. Critical liquidity crisis: current ratio of 0.51x indicates insufficient current assets to cover liabilities.

What is VSEEW's revenue and growth?

Vsee Health, Inc.. reported revenue of $14.6M.

Does VSEEW pay dividends?

Vsee Health, Inc.. does not currently pay dividends.

Where can I find VSEEW SEC filings?

Official SEC filings for Vsee Health, Inc.. (CIK: 0001864531) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is VSEEW's EPS?

Vsee Health, Inc.. has a diluted EPS of $-0.73.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is VSEEW a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Vsee Health, Inc.. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is VSEEW stock overvalued or undervalued?

Valuation metrics for VSEEW: ROE of -269.8% (sector avg: 16%), net margin of -100.6% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.

Should I buy VSEEW stock in 2026?

Our dual AI analysis gives Vsee Health, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is VSEEW's free cash flow?

Vsee Health, Inc..'s operating cash flow is $-3.4M, with capital expenditures of $29.9K. FCF margin is -23.8%.

How does VSEEW compare to other Services stocks?

Vs Services sector averages: Net margin -100.6% (avg: 10%), ROE -269.8% (avg: 16%), current ratio 0.51 (avg: 1.5).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 18, 2026 | Data as of: 2025-12-31 | Powered by Claude AI